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Summary: 
 
DAXX and or ATRX loss occur in 40% of Pancreatic Neuro-endocrine Tumors (PanNETs). 
PanNETs negative for DAXX or ATRX show an increased risk of relapse. The tumor-associated 
pathways activated upon DAXX or ATRX loss and how this event may induce Chromosomal 
Instability (CIN) and Alternative Lengthening Telomeres (ALT) are still unknown. Both DAXX 
and ATRX are involved in DNA methylation regulation. DNA methylation of heterochromatin 
and of non-coding sequences is extremely important for the maintenance of genomic stability. 
We analysed the association of DAXX and or ATRX loss and CIN with global DNA methylation 
in human PanNET samples and the effect of DAXX knock down on methylation and cell 
proliferation. 
We assessed LINE1 as well as global DNA methylation in 167 PanNETs and we found that 
DAXX and or ATRX negative tumors and tumors with CIN were hypo-methylated. DAXX 
knock-down in PanNET cell lines blocked cells in G1/G0 phase and seemed to increase CIN in 
QGP-1 cells. However, no direct changes in DNA methylation were observed after DAXX knock 
down in vitro.  
In conclusion our data indicate that epigenetic changes are crucial steps in the progression of 
PanNETs loss and suggest that DNA methylation is the mechanism via which CIN is induced, 
allowing clonal expansion and selection.  
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Introduction 1 
The molecular pathways and mechanisms underlying initiation and progression of pancreatic 2 
neuroendocrine tumors (PanNET) are still poorly understood. Mutations in DAXX (Death 3 
Domain Associated Protein) and ATRX (ATR-X) with correspondent loss of protein expression in 4 
the tumor tissue occur in 40% of PanNETs (Jiao, et al. 2011). DAXX and or ATRX loss 5 
correlates with Chromosomal Instability (CIN) and predicts for relapse in low stage patients 6 
(Stage I to III in the absence of distant metastasis) (Marinoni, et al. 2014). DAXX and or ATRX 7 
negative tumors show Alternative Lengthening of Telomeres (ALT), a telomerase independent 8 
mechanism for telomere length maintenance, based on homologous recombination (Heaphy, et al. 9 
2011). The mechanisms and the sequence of events linking DAXX/ATRX mutation, ALT and CIN 10 
are unknown.  11 
In addition to mutations, the importance of epigenetic changes is increasingly recognized for 12 
many cancer types (reviewed in (Das and Singal 2004). DAXX and ATRX participate in 13 
maintaining the epigenetic status of the cells by regulating both DNA methylation and H3.3 14 
deposition at telomeric and peri-centromeric regions. DAXX interacts and recruits DNA methyl-15 
transferase enzyme 1 (DNMT1) to specific promoters including RASSF1 and RELB (Puto and 16 
Reed 2008). ATRX contains the ADD domain as does DNMT3-DNMT3L, important for 17 
establishing and maintaining DNA methylation pattern (Noh, et al. 2016).  18 
Impairment of DNA methylation in PanNETs has been shown in several genes (VHL, cdkn2a 19 
(p16), RASSF1, DAPK1, TIMP3, PAX5, HIC1, CADM1, PYCARD, ESR1, VHL, RARB, WT1 and 20 
MGMT). (House, et al. 2003; Malpeli, et al. 2011; Schmitt, et al. 2014; Schmitt, et al. 2009; 21 
Stefanoli, et al. 2014). Genome wide methylation profiling of PanNET has shown a difference of 22 
methylation pattern between DAXX and ATRX negative tumors, suggesting that mainly DAXX 23 
loss is driving DNA methylation changes in PanNETs (Pipinikas, et al. 2015).  24 
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DNA methylation not only regulates gene expression, but also genomic stability. Indeed hetero-25 
chromatin and silenced regions are usually hyper-methylated resulting in a highly condensed 26 
chromatin structure not accessible to the transcription machinery. Hypo-methylated DNA regions 27 
are usually highly transcribed. Repetitive and mobile elements such LINE1 (Long Interspersed 28 
Element-1) and ALU (Arthrobacter luteus) sequences are preserved from transcription and 29 
activation by DNA hyper-methylation. Once activated, these sequences move within the genome 30 
and thereby generate chromosomal instability. Hypo-methylation of LINE1 and ALU sequences 31 
occurs in several tumors including PanNETs (Choi, et al. 2007; Stefanoli et al. 2014). It is 32 
currently unknown whether LINE1 and ALU hypo-methylation is directly linked to DAXX and or 33 
ATRX mutation. Regulation of transcription of the telomeric sequences TERRA (Telomeric 34 
repeat containing RNA) and telomere stability is also dependent on the DNA methylation status. 35 
Dnmt1 deficient mouse embryonic stem cells show elongated telomeres, increased recombination 36 
at telomeric regions and ALT activation (Gonzalo, et al. 2006).  37 
In the present study we aimed to analyse the effect of DAXX and or ATRX loss on global 38 
methylation in ex-vivo human PanNETs samples and in vitro in BON-1 and QGP-1 cell line- 39 
models. In vitro we also assessed genomic instability induction upon DAXX knock down. We 40 
found that DAXX and or ATRX negative PanNETs showed global hypo-methylation but not 41 
LINE1 hypo-methylation compare to positive tumors. Additionally we were able to find a link 42 
between LINE1 hypo-methylation and CIN in PanNETs. DAXX knock down does not induce 43 
methylation changes in BON-1 and QGP-1 cells.  44 
 45 
Material and Methods 46 
Human samples 47 
167 out of 207 resected well differentiated PanNETs (G1-G2) and 11 matching control were used 48 
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in the study based on DNA viability and informative IHC results (Marinoni et al. 2014).  49 
 CIN data obtained by Comparative Genomic Hybridization (CGH) were previously reported 50 
(Marinoni et al. 2014). 51 
CIN were defined as showing a total number of gains and losses of 8 or more in conventional 52 
CGH and of 20 or more in array CGH. The use of patient material was approved by the local 53 
ethics committees (Number 105/2015). The composition of samples is described in table 1 and in 54 
the supplementary figure 1. 55 
Cell line culture conditions and treatments 56 
The pancreatic neuroendocrine cell line BON-1 (pancreatic carcinoid) was provided by E.J. 57 
Speel, Department of Pathology, Maastricht, The Netherlands and metastatic somatostatinoma 58 
derived QGP-1 cell line was obtained from Japanese Health Sciences Foundation, Osaka, Japan. 59 
Both cell lines authentication was performed by STRs analysis (Mycrosynth, Balgach, 60 
Switzerland) upon arrival (2011) and in the present year. QGP-1 cells resulted 100% matching 61 
with the QGP-1 profile (GNE586559, Genentech, Roche, Basel, Switzerland).  BON-1 cells are 62 
not commercially available therefore no comparison is possible, however STRs analysis of these 63 
cells revealed no matching with any data available in the ATCC database, excluding any 64 
contamination with other cell lines. Additionally the expression of the neuro-endocrine markers 65 
Synaptophysin and Chromogranin-A was checked yearly. Both QGP-1 and BON-1 cells express 66 
the two markers. Cells were kept in culture for a maximum of 20-25 passages.  67 
Both cell lines were cultured at 37°C under 5% CO2. BON-1 were cultured in DMEM/Nutrient 68 
Mixture F-12 Ham (D6421, Sigma-Aldrich, Buchs SG, Switzerland) and QGP-1 in RPMI 1640 69 
Dutch modification (R7638, Sigma-Aldrich), both media supplemented with 10% FBS (GIBCO, 70 
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Thermo Fisher Scientific, Paisley, UK), 2nM L-alanyl-L-glutamin (Sigma-Aldrich), 100µg/ml 71 
streptomycin and 100units/ml of penicillin (Sigma-Aldrich).  72 
 73 
Immuno-histo-chemistry (IHC) 74 
Four-micrometer sections were taken from a TMA including 207 pNETs derived from patients 75 
who underwent surgery at the Inselspital Bern, Switzerland previously described (Marinoni et al. 76 
2014) and stained with an anti-5-methylcytidine antibody BI_MECY_0100 (Eurogentec, Kaneka, 77 
Liege, Belgium). The Immunohistochemical staining was performed on an automated staining 78 
system (Leica Bond III; Leica Biosystems, Nunningen, Switzerland). Antigen retrieval was 79 
performed by heating citrate buffer at 100° for 30 minutes. The primary antibody was incubated 80 
for 30 minutes at a dilution of 1:200. Visualization was performed using the avidin-biotin 81 
complex method, which yielded a brown staining signal. Normal pancreatic islets show strong 82 
positive staining indicating a certain level of DNA methylation thus we scored as high-83 
methylated samples showing similar or stronger staining than normal islets and low-methylated 84 
samples showing weaker staining. To exclude false-negative samples, only samples with positive 85 
nuclear staining of non-neoplastic cells and negative tumor nuclei were scored as negative (153 86 
of 207 samples remaining informative). 54 Samples with both negative tumor nuclei and non-87 
neoplastic stromal and endothelial cells were scored as non-informative and excluded from 88 
further analysis. 89 
 90 
DNA extraction, bisulfite conversion and global methylation analysis 91 
DNA was extracted from cell pellet of about 6x10
5
 cells or from paraffin embedded human 92 
PanNETs (55 tumor samples with more than 80% tumor content and 11 matching normal 93 
pancreatic tissues, Table 1 and supplementary figure 1) using Nucleo Spin kit by Macherey-94 
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Nagel (Düren, Germany) according to the manufacturer’s instructions. For bisulfite conversion of 95 
gDNA the EZ DNA Methylation-Gold kit by Zymo Research Corporation (Freiburg, Germany) 96 
was used following the manufacturer’s instructions.  97 
Genomic DNA of 10 tumor samples was analyzed by its global methylation status using 98 
EpiSeeker methylated DNA Quantification Kit (ab117128, Abcam, Cambridge, United 99 
Kingdom), according to the supplier’s instructions. Colorimetric measurements were done on an 100 
ELISA reader (Tecan, Männerdorf, Switzerland). Hyper-methylated and hypo-methylated DNAs 101 
(Zymo Research) were used as controls. 102 
PCR and pyrosequencing investigation for LINE-1 for 51 samples (GenBank accession number 103 
X58075) methylation analysis was performed using PyroMark kit (Qiagen, Hilden, Germany). To 104 
analyse sequence methylation of LINE-1, the PyroMark Q24 CpG LINE-1 (4x24) Methylation 105 
detection assay was used (Qiagen). Amplifications were performed with Master Mix PyroMark 106 
PCR Kit (Qiagen) according to supplier’s instructions on a Veriti System gradient apparatus 107 
(Applied Biosystems, Thermo Fisher Scientific). PCR product was bound to Streptavidin 108 
Sepharose HP (Amersham Biosciences, GE Healthcare, Little Chalfont, United Kingdom), 109 
purified, washed, denatured and washed again with the PyroMark Q24 Vacuum Workstation 110 
220V (Qiagen). Pyrosequencing was performed using the Qiagen PyroMark Q24 System with the 111 
pyromark Q24 Cartridge Method 0011 (Qiagen). The assay setups and analysis were performed 112 
with PyroMark Assay Design Software V.1.0.6 (Qiagen).  113 
MGMT (O
-
6-methylguanine-DNA-methyltransferase) promoter methylation was assessed in 25 114 
tumor samples as previously described (Vassella, et al. 2011). Samples with methylation level 115 
higher and equal to 5% were considered hyper-methylated and samples with methylation level 116 
<5% were considered hypo-methylated.  117 
Page 7 of 26
8 
 
The MEN1 gene was analysed in 26 tumor samples by semi-conductive sequencing using an Ion 118 
Torrent PGM (Life Technologies). Protein coding exons were amplified by multiplex polymerase 119 
chain reaction using 2 primer pools designed by the Ion AmpliSeq Designer (Life Technologies). 120 
Library construction, emulsion polymerase chain reaction, and sequencing were performed 121 
according to the manufacturer’s recommendations. The Torrent Suite 5.0.3 platform was used for 122 
sequence alignment with the hg19 human genome reference. Variant calling was performed with 123 
the variant caller 5.0.3.5. and the IonReporter 5.0 software (Life Technologies, Grand Island, 124 
NY). The average base coverage depth for most samples was more than 2000 reads. MEN1 125 
mutations found are summarized in table 1 in the Supplementary Material.  126 
DAXX knock down 127 
For virus infection 6x10
5
 cells were seeded in 6 wells plate the day before. pLKO.1 lentiviral 128 
vectors expressing small hairpin (sh) RNAs targeting DAXX (Sh-DAXX_H2410: and Sh-129 
DAXX_2503) or a nontargeting shRNA control (SHCOO2) were purchased from Sigma-Aldrich 130 
Lentiviral production and transduction were done as described in (Tschan, et al. 2003).  131 
Transduced cells were selected by puromycin treatment (1.5µg/ml, Invitrogen). For micro-nuclei 132 
counting, cells were seeded in 24-well plates on coverslips coated with FBS, 1x10
4
 cells per well. 133 
Cells were fixed with 4% Paraformaldehyde for 30 min at room temperature. DAPI was used to 134 
stain nuclei. Micronuclei were counted under a fluorescent microscope (Axiophot2, Zeiss).  135 
Viability and apoptosis assays 136 
For MTT assay cells were seeded into 96-well plates at the density of 16’000 cells per well. After 137 
24h medium was replaced by 100ul of medium with 10% MTT (0.5mg/ml final concentration) 138 
(Sigma-Aldrich) and incubate 1h at 37°. After incubation the medium was removed and 200 µl of 139 
DMSO (Sigma-Aldrich) and 25 µl of Sorensen solution (0.1M Glycine, 0.1M NaCl, pH 10.5 in 140 
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water) were added into each well. Absorbance at 570nm was determined on a spectrophotometer 141 
(Tecan). 142 
Cell cycle analysis with FACS 143 
Briefly, cells were seeded 5x10
5
 cells in duplicates or triplicates in 6-well plates. The day after 144 
cells were treated with Nocodazol. After 16h of treatment cells were fixed in ice cold EtOH 145 
overnight. PI staining was performed directly before measurement on BD-FACS LSR SorpII 146 
using BD FACSDiva 6.1 software (BD Bioscience, Heidelberg, Germany). Results were 147 
analyzed using FlowJo v9.8 software (TreeStar, USA). 148 
Protein extraction and Western blot analysis 149 
For western blotting Cells were cultivated in 6-well plates and lysate in Urea buffer. Forty ng 150 
proteins were loaded on 4-20% Mini-PROTEAN® TGX Stain-Free™ Gel (Bio-Rad, Cressier, 151 
Switzerland). Transfer was performed using transfer turbo blot system (Bio-Rad). Primary 152 
monoclonal antibodies rabbit anti DAXX (clone 25C12, 1:1000 in 5% BSA, Cell signaling, 153 
Cambridge, United Kingdom) and mouse anti human α-tubulin (clone B-5-1-2, 1:1000 in 5% 154 
BSA, Sigma), GAPDH (clone 6c5, 1:1000 in 5% skimmed milk, Merk Millpore, Darmstadt, 155 
Germany) were used. As secondary antibodies goat anti-rabbit DyLight® 650 conjugate 156 
(LabForce, Muttenz, Switzerland) and goat anti-mouse DyLight® 550 conjugate (LabForce) both 157 
diluted 1:500 in 5% milk were used. Signal was detected with ChemiDoc MP System (Bio-Rad) 158 
and analyzed in ImageJ (freeware, 1.48v, Bethesda, USA). Protein levels were normalized to α-159 
tubulin, GAPDH or total protein.  160 
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Statistics 161 
Statistical analysis was performed using GraphPAD prism 5 software (La Jolla, CA, USA). 162 
Statistical differences were calculated using unpaired two-tailed Student’s t test. The χ
2
 test or the 163 
Fisher exact test was used to calculate contingency tables. P values less than .05 were considered 164 
statistically significant. 165 
 166 
Results 167 
Ex-vivo analysis of human PanNET samples 168 
DAXX and or ATRX negative PanNET are hypo methylated 169 
In order to first assess whether DAXX/ATRX loss had an impact on the DNA methylation 170 
pattern we evaluated global DNA methylation on 10 PanNET samples. DNA extracted from 5 171 
PanNET samples positive for DAXX/ATRX IHC staining, negative for ALT activation and CIN 172 
negative (DAXX/ATRX+/ALT-/CIN-) and from 5 PanNET samples negative for DAXX/ATRX 173 
staining, positive for ALT activation and CIN positive (DAXX/ATRX-/ALT+/CIN+) were 174 
analyzed for global DNA methylation with the colorimetric EpiSeeker assay (Methylated DNA 175 
Quantification Kit, Abcam). As shown in figure 1-A DAXX/ATRX-/ALT+/CIN+ tumors exhibit 176 
a significantly lower level of DNA methylation compared to DAXX/ATRX+/ALT-/CIN- ones 177 
(p<0.01**), which is comparable to the un-methylated control. To confirm our findings in a 178 
larger setting and with an additional method, we stained 2 TMAs, composed as described in the 179 
material and methods section and in (Marinoni et al. 2014) with an anti-5-methylcytidine 180 
antibody (Eurogentec) that specifically recognizes the methylated base and does not cross-react 181 
with the un-methylated one. We obtained results on 153 samples; the characteristic of these 182 
samples is reported in table 1.  183 
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We observed that strong 5-methylcytidine staining associates with DAXX and ATRX proficient 184 
tumors while weak signal correlates with DAXX/ATRX deficient ones p<0.05* (Figure 1 B-G 185 
and Table 2), suggesting that DAXX/ATRX deficient tumor show global hypo-methylation 186 
compared to the positive ones. Normal islets showed a strong 5-methylcytidine staining (Figure 1 187 
B-C).  188 
To examine the DNA methylation level of non-coding regions we evaluated the (Long 189 
Interspersed Element) LINE1 methylation status as a marker of global DNA methylation in 55 190 
PanNET and 11 non-neoplastic pancreatic specimens, by pyro-sequencing (Qiagen). We 191 
observed that LINE1 is hypo-methylated in PanNETs compared to normal pancreas (p<0.001***) 192 
(Figure 2-A) as previously reported (Choi et al. 2007; Stefanoli et al. 2014). LINE1 hypo-193 
methylation indeed associates with CIN (p<0.05*) (Figure 2-B), as we hypothesized. However, 194 
no differences in LINE1 methylation were observed in either DAXX/ATRX positive and 195 
negative tumors, ALT positive and negative (Figure 2 C-E). In order to assess if MEN1 196 
mutations impact on LINE1 methylation levels we sequenced MEN1 gene in 26 samples. Eleven 197 
samples resulted to be mutated. The mutations found are summarized in Supplementary Material 198 
Table 1. No difference in LINE1 methylation status were observed between mutant and wild type 199 
tumors (Figure 2 F).  Interestingly, LINE1 hypo-methylation predicts for shorter disease free 200 
survival (p<0.05*), (figure 3 supplementary material) in agreement with the results reported by 201 
Stefanoli et al. (Stefanoli et al. 2014); while no differences in survival are detectable in tumors 202 
positive and negative for 5-methylcytidine staining (data not shown).   203 
We performed quantitative methylation specific PCR to assess whether LINE1 hypo-methylation 204 
or DAXX/ATRX loss correlate with hyper-methylation of MGMT promoter, due to its clinical 205 
relevance. We found 8 samples with MGMT promoter hyper-methylated and 17 samples where 206 
MGMT promoter was un-methylated. No correlation between LINE1 hypo-methylation or 207 
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DAXX/ATRX loss and MGMT methylation level was found (Supplementary Figure 4), 208 
suggesting two independent mechanisms for the two events, as previously proposed (Stefanoli et 209 
al. 2014).  210 
 211 
In vitro upon DAXX knock-down 212 
Induction of genomic instability and G1 arrest 213 
In order to assess if DAXX loss is sufficient to induce genomic instability, we knocked down 214 
DAXX in two PanNET cell lines, QGP-1 and BON-1 by Lentiviral transduction of SH-RNAs. 215 
DAXX knock down was evaluated by western blotting 9, 17 and 24 days after lentiviral 216 
infection. Two different DAXX specific vectors (1 and 2) and scramble control were used in both 217 
cell lines. DAXX expression is highly reduced after 9 days from infections in both cell lines 218 
(Figure 3-A and supplementary material Figure 5-A). After 17 days DAXX expression is down-219 
regulated to a lesser extent while both cell lines re-express DAXX after 24 days. Therefore, all 220 
experiments were performed within the first 10 days after infection. Of note, the knock down 221 
efficiency was higher with vector SH-DAXX-1 than SH-DAXX-2; consistently we observed a 222 
stronger phenotype on the cells transduced with the first vector.  223 
Interestingly, we observed that in QGP-1 cells DAXX knock down induced an increased number 224 
of micronuclei formation and anaphase bridges while no micro-nuclei formation was observed in 225 
BON-1 cells. DAXX knock down QGP-1 cells showed an increased number of micronuclei 226 
formation compared to scramble (Figure 3 B-D). This result suggests an increased genomic 227 
instability induced by DAXX loss in QGP-1 cells.  228 
DAXX knock down in both QGP-1 and BON-1 does not induce ALT activation as detected by 229 
telomere FISH in vitro (data not shown), similarly to what has been shown by others in ATRX 230 
knock down cells (Napier, et al. 2015).  231 
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DAXX knock down reduced cell viability, measured by MTT assay (Figure 3-E and 232 
supplementary material Figure 5-B), indicating that DAXX has not a classical tumor suppressor 233 
gene function.   No significant increase in apoptosis was observed in DAXX knock down 234 
samples compared to the scramble control (Supplementary Figure 6). FACS analysis revealed 235 
that DAXX knock down induces G1 arrest in both BON-1 cells and QGP-1 (Figure 3-F and 236 
Supplementary Figure 7).  237 
 238 
Short time DAXX knock down does not affect LINE1 and global methylation.  239 
Since in human samples we observed that DAXX and or ATRX loss correlates with DNA hypo-240 
methylation we wanted to investigate whether DAXX knock down impairs DNA methylation in 241 
vitro as well. No difference in LINE1 methylation as well as global methylation were observed 242 
after 10 days of DAXX knock down in both BON-1 and QGP-1 cells (Supplementary Figure 8 243 
and data not shown). Similarly, no difference in MGMT promoter methylation were observed 244 
upon DAXX knock down (data not shown).  245 
 246 
Discussion 247 
The sequence of the events and the mechanism by which DAXX and or ATRX loss induces ALT 248 
and CIN are still unknown. Here we provide evidence, that epigenetic mechanisms could be 249 
involved in this process. In detail, we showed by immunohistochemistry and biochemical 250 
methods that DAXX and or ATRX negative PanNET are globally hypo-methylated. Hypo-251 
methylation of repeated sequences has been described in several cancers in correlation with 252 
progressive increase of the grade of malignancy (Ehrlich 2002). Long interspersed nuclear 253 
elements (LINE1) are the most abundant mobile DNAs in the human genome and hypo-254 
methylation of these sequences has been shown in different type of cancer including PanNETs 255 
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(Choi et al. 2007; Stefanoli et al. 2014). Indeed, we could confirm that LINE1 is hypo-methylated 256 
in PanNET compared to normal pancreas. Here we additionally showed that PanNETs showing 257 
CIN have a lower level of LINE1 methylation than chromosomally stable PanNET. We 258 
previously showed that DAXX and or ATRX loss in PanNETs correlates with CIN (Marinoni et 259 
al. 2014).  We hypothesize that DAXX and ATRX loss in PanNET cells result in a decreased 260 
DNA methylation thus promoting CIN. Indeed, we found that DAXX/ATRX negative PanNET 261 
show lower level of global methylation assessed by IHC and by a colorimetric assay.  262 
However, we could not find a correlation between DAXX and or ATRX loss, ALT activation and 263 
LINE1 methylation. LINE1 methylation could therefore be mediated by other unknown events. 264 
On the other hand, a multi-step model in which DAXX and ATRX loss progressively impairs 265 
DNA methylation and chromatin structure would also explain this discrepancy. Indeed, our cell 266 
line results could point into this direction: Short time DAXX knock down did not induce any 267 
changes in global or LINE1 DNA methylation. Either DAXX knock down is not sufficient to 268 
induce global hypo-methylation without other events, or it is instead a matter of time and 269 
additional cell cycles are needed.  270 
Impairment of DNA methylation, particularly at telomeres has been described in glioblastoma 271 
with ALT activation as well as in Astrocytoma with low ATRX expression (Cai, et al. 2015; 272 
Sturm, et al. 2012). Recently it has been shown that DAXX deficient PanNET showed higher 273 
methylation variation compared to ATRX negative ones (Pipinikas et al. 2015). However this 274 
report did not focus on global methylation levels, which could largely be influenced by non-275 
coding sequences, such as LINE1 and telomeric regions. 276 
A reduction of methylation in the subtelomeric regions, allowing DNA recombination, might also 277 
promote ALT activation (Gonzalo et al. 2006). Upon DAXX knock-down in PanNET cell lines 278 
we did not observed ALT activation, in keeping with other finding showing that DAXX and 279 
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ATRX loss does not induce ALT activation in vitro in telomerase positive cells (Napier et al. 280 
2015). In QGP-1 cells we observed a higher number of micronuclei upon DAXX knock down 281 
compared to control which might be a sign of increased genomic instability already at this short 282 
time-point and without ALT phenotype and impairment in DNA methylation. However, the small 283 
percentage, of cells showing micro nuclei formation upon DAXX knock out might not be 284 
sufficient to detect DNA methylation changes when this is assessed in the whole cell population.  285 
The phenotype of DAXX knock down cells has confirmed the non-conventional tumor 286 
suppressor role. DAXX silencing in vitro in BON-1 and QGP-1 cells induced G1/G0 cell cycle 287 
arrest. Similarly, ATRX knock down in other tumor models reduced cell proliferation and 288 
induced genomic instability (Cai et al. 2015; Huh, et al. 2016; Huh, et al. 2012; Lovejoy, et al. 289 
2012). It is important to point out that BON-1 and QGP-1 cells are mainly a model for G3 290 
PanNECs with mutations in genes, which are usually not altered in G1-G2 PanNETs (i.e. TP53) 291 
(Vandamme, et al. 2015). In this context DAXX knock down may impact on the cell cycle 292 
regulation and genomic instability differently than in the slow progressive tumors with a different 293 
mutational spectrum.  Additionally the difference in the mutations background between QGP-1 294 
and BON-1 may explain the different results in the micronuclei formation. Recently it has been 295 
shown that Daxx knock-down in a rat insulinoma cell line increased cell proliferation, suggesting 296 
that this model might be more appropriate for Daxx functional studies (Feng, et al. 2016). 297 
However rodent cells usually show minor and different genomic instability pattern compared to 298 
human cells and they rarely activate ALT mechanism for telomeres lengthening, even in absence 299 
of telomerase (Hermsen, et al. 2015) (Argilla, et al. 2004). This suggests that even this model 300 
harbours some limitation in the study of DAXX loss impact on genomic instability, ALT 301 
activation and DNA methylation which was the main focus of our work.  302 
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Our finding very likely only show a part of a more complex situation as other factors than DAXX 303 
and ATRX mutation can influence the epigenetic status. DAXX and or ATRX loss is frequently 304 
accompanied by MEN1 mutations and this possibly contributes to the epigenetic status. MEN1 is 305 
mutated in almost 44% of sporadic PanNETs (Jiao et al. 2011). MEN1 gene, encodes the 306 
transcription factor menin, which recruits the H3K4me3 histone methyltransferase mixed lineage 307 
leukaemia (MLL1) complex that plays an essential role in chromatin remodelling and gene 308 
expression (Agarwal, et al. 1999; Agarwal and Jothi 2012; Yang, et al. 2013). However MEN1 309 
mutations in PanNETs are not associated with CIN nor with ALT phenotype. In agreement with a 310 
model of epigenetically induced CIN, our results showed no correlation between LINE1 311 
methylation level and MEN1 mutation status. Similarly we did not detect any correlation between 312 
global methylation assessed by IHC and MEN1 mutations (data not shown).  313 
In conclusion our data provide evidence that DAXX and ATRX loss impact on global DNA 314 
methylation of PanNETs cells, which seem to be involved in chromosomal instability. This could 315 
enable PanNET to acquire clonal heterogeneity leading to a selection of more aggressive clones. 316 
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Figure legends:  421 
 422 
Figure 1:  Global methylation in PanNETs. A) Global methylation levels of DNA isolated from 423 
human PanNETs using EpiSeeker methylated DNA Quantification Kit (Abcam). Highly 424 
methylated DNA and unmethylated DNA were used as controls. DAXX/ATRX-/ALT+/CIN+ 425 
tumors showed hypo-methylation compared to DAXX/ATRX+/ALT-/CIN- ones (p<0.01**). B-426 
G) IHC with anti-5-methylcytidine antibody (Millipore) on human tissues. (B-C) Normal 427 
pancreas: (*) pancreatic islets and (**) exocrine pancreas. D-E two PanNETs samples showing 428 
low 5-methlycytidine expression and F-G two PanNET samples showing high 5-methylcytidine 429 
expression. 430 
 431 
Figure 2: LINE-1 methylation in PanNETs. A) PanNET samples showed a significant lower 432 
level of methylation compared to normal surrounding tissues (p<0.001*). B) PanNETs with high 433 
CIN showed a lower level of LINE1 methylation (p<0.05) compared to tumors with no CIN. C-434 
D) DAXX/ATRX- tumors and ALT+ tumors do not show difference in LINE1 methylation 435 
compared to respectively DAXX/ATRX+ and ALT- tumors. E) Tumors which are both 436 
DAXX/ATRX- and ALT+ did not show difference in LINE1 methylation level compared to 437 
tumors, which are DAXX/ATRX+ and ALT-, F) MEN1 mutated and wild type PanNET do not 438 
show differences in LINE1 methylation levels.  439 
Page 19 of 26
20 
 
 440 
Figure 3: DAXX knock-down in QGP-1 cell lines. A) Western blotting showing DAXX knock-441 
down after 9, 17 and 24 days upon infection with two different plasmids SH-DAXX-1 and SH-442 
DAXX-2 in QGP-1. Parental (Par.) cells and cells transduced with scramble vector (Scr.) were 443 
used as controls. DAXX expression comes back to normal level after 24 days from the infection. 444 
Quantification of the knock-down after 9 and 17 days from infection was based on three different 445 
experiments. B) DAPI staining of QGP-1 cells after DAXX knock-down; arrows indicate an 446 
anaphase bridge and micronuclei. C) Fold changes of the number of micronuclei (MN) per cells 447 
compare to scramble. D) Number of anaphase bridges compare to mitosis. SH-DAXX-1 and SH-448 
DAXX-2 cells showed an increased on micronuclei and anaphase bridges compared to controls. 449 
E) Graphic representation of MTT viability assays after 8 days and after 16 days from infection. 450 
DAXX knock-down impairs cell viability. After 16 days when DAXX expression is restored to 451 
normal levels, the cells proliferate as the controls, suggesting a direct effect of DAXX on cell 452 
viability. F) FACS analysis of QGP1 cells after DAXX knock-down. Cells knocked-down for 453 
DAXX showed an increased in the percentage of cells in G1/G0 compared controls. The results 454 
are based on at least three repetitions.  455 
 456 
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Table 1: Characteristics of the human sample collective 
 
Collective  
Total patients (IHC 
plus LINE1 and 
Global 
methylation) IHC 
LINE1 and global 
methylation  
Tot 167 153 55 
Female 82 75 26 
Male 83 76 28 
 2 2 1 
Age average 56,66 56,09 55,21 
G1 119 107 33 
G2 48 46 22 
T1 61 53 13 
T2 46 44 18 
T3-4 45 41 23 
n.a. 15 15 1 
N0 58 54 15 
N1 39 36 24 
n.a. 70 63 16 
M0 95 85 34 
M1 30 30 12 
n.a. 42 38 9 
DAXX/ATRX + 74 67 13 
DAXX/ATRX- 47 44 30 
n.a. 46 42 12 
DAXX- 23 23 3 
DAXX+ 106 97 38 
n.a. 38 33 14 
ATRX- 28 25 13 
ATRX+ 95 88 33 
n.a. 44 40 9 
ALT- 59 53 16 
ALT+ 39 37 20 
n.a. 69 63 19 
CIN-  22  15 11 
CIN+ 30 26 11 
n.a. 115 112 33 
MEN1 wt 15 15 15 
MEN1 mut 11 11 11 
n.a. 141 127 29 
MGMT hyper    8 
MGMT hypo   17 
   30 
RFS (months)     52 (data based on 44 patients) 
TSS (months)     80 (data based on 44 patients) 
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Table legend: G (Grade), T (Tumor Stage), N (lymph node metastasis), M (Distant Metastasis) ALT 
(Alternative Lengthening Telomeres), CIN (Chromosomal Instability), RFS (Relapse free Survival), 
TSS (Tumor Specific Survival).  
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Table 2: Correlation between DAXX/ATRX expression and 5-methylcytidine staining in human PanNET 
tissues. 
 
  Low 5-metyl-cytidine High 5-metyl-cytidine p value 
DAXX/ATRX- 28 15 0.019* 
DAXX/ATRX+ 28 39 
DAXX- 17 6 0.020* 
DAXX+ 44 52 
ATRX- 15 13 0.517 
ATRX+ 40 48 
ALT- 25 28 0.338 
ALT+ 21 15 
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